Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isomalto-oligosaccharide sulfate
- Development stage
- Preclinical
- Lead developer
- Herbon International Polysaccharide Biotechnology
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intraperitoneal
01
Overview
Isomalto-oligosaccharide sulfate (IMOS) is a novel sulfated oligosaccharide small molecule drug being developed for the treatment of hepatocellular carcinoma (HCC). Structurally, it is composed of four sulfated isomaltose molecules with a molecular weight of less than 1500 Da. Developed by Herbon Polysaccharide Bio-tech, IMOS acts as a multi-pathway inhibitor that suppresses tumor growth and metastasis by down-regulating the ERK and JNK signaling pathways and reducing the expression of the c-MET protein. Preclinical studies have demonstrated that IMOS inhibits cancer cell proliferation, induces apoptosis, and impairs cell adhesion, migration, and invasiveness. It is structurally distinct from other sulfated oligosaccharide anticancer agents like PI-88 and is designed to target the tumor microenvironment and intracellular signaling independent of p53 status.
- Other names
- isomalto oligosaccharide sulfate
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)HPSE (Heparanase)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on isomalto-oligosaccharide sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isomalto-oligosaccharide sulfate.